AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
hexachlorophene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1364 | 70-30-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 59 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,GSK3A,MAP2K6,MAPK1,MAPK7,PDK4,PIK3CB,PIK3CD,SIK2,STK33,TEK | 16 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 19, 1949 | FDA | SANOFI AVENTIS US |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vascular malformation | 170.15 | 144.16 | 22 | 416 | 730 | 90627279 |
| Paranasal cyst | 168.52 | 144.16 | 22 | 416 | 788 | 90627221 |
| Mastoiditis | 152.60 | 144.16 | 22 | 416 | 1648 | 90626361 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vascular malformation | 180.95 | 173.54 | 23 | 429 | 791 | 110588056 |
| Paranasal cyst | 178.53 | 173.54 | 23 | 429 | 881 | 110587966 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D08AE01 | DERMATOLOGICALS ANTISEPTICS AND DISINFECTANTS ANTISEPTICS AND DISINFECTANTS Phenol and derivatives |
| FDA EPC | N0000175486 | Antiseptic |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000891 | Anti-Infective Agents, Local |
| CHEBI has role | CHEBI:22153 | acaricide |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:48218 | antiseptic drug |
| CHEBI has role | CHEBI:86328 | antifungal agrochemical |
Related Drugs by ATC class:
D08AE Phenol and derivatives 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Burn injury | contraindication | 48333001 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Denuded skin | contraindication | 418242004 | |
| CNS Toxicity | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.2 | acidic |
| pKa2 | 8.97 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | IC50 | 6.19 | DRUG MATRIX | |||||
| Adenosine receptor A2a | GPCR | Ki | 6.04 | DRUG MATRIX | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 5.69 | DRUG MATRIX | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.64 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.44 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.62 | DRUG MATRIX | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 5.99 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 6.44 | DRUG MATRIX | |||||
| Estrogen receptor | Nuclear hormone receptor | IC50 | 5.67 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | IC50 | 5.52 | DRUG MATRIX | |||||
| Estrogen receptor beta | Nuclear hormone receptor | IC50 | 7.01 | CHEMBL | |||||
| Cytochrome P450 1A2 | Enzyme | IC50 | 5.88 | DRUG MATRIX | |||||
| Epidermal growth factor receptor | Kinase | IC50 | 6.13 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 5.91 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Lck | Kinase | IC50 | 5.61 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.46 | DRUG MATRIX | |||||
| Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 5.48 | DRUG MATRIX | |||||
| Thromboxane-A synthase | Enzyme | IC50 | 5.51 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 3 | Kinase | IC50 | 5.61 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 14 | Kinase | IC50 | 7.06 | DRUG MATRIX | |||||
| Substance-K receptor | GPCR | Ki | 5.86 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 1 | Kinase | IC50 | 6.71 | DRUG MATRIX | |||||
| Transitional endoplasmic reticulum ATPase | Enzyme | IC50 | 5.26 | CHEMBL | |||||
| Heat shock cognate 71 kDa protein | Cytosolic other | IC50 | 4.56 | CHEMBL | |||||
| Heat shock 70 kDa protein 1A | Cytosolic other | IC50 | 4.72 | CHEMBL | |||||
| Macrophage migration inhibitory factor | Cytokine | Ki | 5.26 | CHEMBL | |||||
| N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D | Enzyme | INHIBITOR | IC50 | 5.01 | IUPHAR | ||||
| 78 kDa glucose-regulated protein | Cytosolic other | IC50 | 5.04 | CHEMBL | |||||
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| D-lactate dehydrogenase | Enzyme | WOMBAT-PK | |||||||
| Androgen receptor | Transcription factor | Ki | 5.48 | DRUG MATRIX | |||||
| Zinc finger protein mex-5 | Cytosolic other | EC50 | 4.72 | CHEMBL | |||||
| M1-family alanyl aminopeptidase | Enzyme | IC50 | 4.24 | CHEMBL | |||||
| Cytoplasmic zinc-finger protein | Cytosolic other | EC50 | 4.34 | CHEMBL | |||||
| Envelope glycoprotein gp160 | Viral envelope protein | IC50 | 5.14 | CHEMBL | |||||
| Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Viral envelope protein | IC50 | 5.14 | CHEMBL | |||||
| Sodium/potassium-transporting ATPase subunit alpha-2 | Ion channel | IC50 | 5.21 | DRUG MATRIX | |||||
| N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, N-acyl phosphatidylethanolamine phospholipase D, NAPE-PLD, NAPE-hydrolyzing phospholipase D, EC 3.1.4.54 | Enzyme | IC50 | 4.96 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018252 | VUID |
| N0000146582 | NUI |
| D00859 | KEGG_DRUG |
| 4018252 | VANDF |
| C0019435 | UMLSCUI |
| CHEBI:5693 | CHEBI |
| CHEMBL496 | ChEMBL_ID |
| D006582 | MESH_DESCRIPTOR_UI |
| DB00756 | DRUGBANK_ID |
| 3598 | PUBCHEM_CID |
| 11069 | IUPHAR_LIGAND_ID |
| 2033 | INN_ID |
| IWW5FV6NK2 | UNII |
| 5293 | RXNORM |
| 4826 | MMSL |
| 71944 | MMSL |
| 741 | MMSL |
| 003176 | NDDF |
| 1878008 | SNOMEDCT_US |
| 387103004 | SNOMEDCT_US |
Pharmaceutical products:
None